title: Indomethacin treatment decreases renal blood flow velocity in human neonates.
abstract: This study was designed to evaluate the effect of indomethacin (ID) on renal perfusion in 13 neonates with symptomatic patent ductus arteriosus (PDA). Serial blood flow velocity in the left renal artery was measured just before and at 10, 30, 45, 60, 75 and 90 min after ID administration. Serum creatinine (Cr), sodium (Na), and osmolarity were measured just before, at 12 and 24 h, and at 3 days after ID administration. Timed urine also was collected for measurement of amount, fractional excretion of Na (FE(Na)), and creatinine clearance (C(Cr)). ID decreased end-diastolic flow velocity of renal artery and increased Pourcelot's index, starting at 10 min and lasting for 75 min (p < 0.05). Serum Cr significantly increased at 12 h, and hourly urine output and C(Cr) decreased for 24 h. Serum Na and osmolarity decreased for a period of at least 3 days (p < 0.05). FE(Na) decreased at 12-24 h (p < 0.05). We conclude that ID treatment can induce significant renal dysfunction due to diminution of renal perfusion in human neonates.
authors.affiliation: Department of Pediatrics, College of Medicine, Korea University, Seoul, Korea.
authors.forename: N S
authors.initials: NS
authors.lastname: Kang
authors.forename: K H
authors.initials: KH
authors.lastname: Yoo
authors.forename: H
authors.initials: H
authors.lastname: Cheon
authors.forename: B M
authors.initials: BM
authors.lastname: Choi
authors.forename: Y S
authors.initials: YS
authors.lastname: Hong
authors.forename: J W
authors.initials: JW
authors.lastname: Lee
authors.forename: S K
authors.initials: SK
authors.lastname: Kim
mesh_terms: D001724:Birth Weight; D001783:Blood Flow Velocity / Q000187:drug effects; D003404:Creatinine / Q000097:blood / Q000652:urine; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D007262:Infusions, Intravenous; D007674:Kidney Diseases / Q000139:chemically induced* / Q000503:physiopathology; D008297:Male; D009994:Osmolar Concentration; D011446:Prospective Studies; D012077:Renal Artery / Q000187:drug effects / Q000503:physiopathology; D012079:Renal Circulation / Q000187:drug effects* / Q000502:physiology; D012964:Sodium / Q000097:blood / Q000652:urine; D018615:Ultrasonography, Doppler, Color; D014554:Urination / Q000187:drug effects
chemical_list: D016861:Cyclooxygenase Inhibitors; D012964:Sodium; D003404:Creatinine; D007213:Indomethacin